Search
Coeptis Therapeutics Holdings Inc
COEPAdd to Watchlist
16.400USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
579.55MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+12.02%
Year to Date
+15.09%
1 Year
+117.51%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
2.17%Turnover Ratio
16.400Prev. Close
0.000Low
0.00Turnover
LossP/E Static
8.16P/B
0.00%Div Yield TTM
-97.97%ROA
21.41052wk High
1.07Volume Ratio
-9.81MNet Profit
5.16MShares
-2.8141EPS TTM
-0.11Beta
-142.32%ROE
6.26052wk Low
8.64%Amplitude
65.76%Gross Margin
579.55MMarket Cap
10.31Reward/Risk
5.02%Risk Rate
TradingKey Stock Score of Coeptis Therapeutics Holdings Inc
Currency: USD Updated: 2026-04-24Key Insights
Coeptis Therapeutics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 197 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Coeptis Therapeutics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Coeptis Therapeutics Holdings Inc Highlights
StrengthsRisks
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.36M.
Undervalued
The company’s latest PE is -5.83, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 562.19K shares, increasing 37.66% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 339.49K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Coeptis Therapeutics Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Coeptis Therapeutics Holdings Inc Info
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Ticker SymbolCOEP
CompanyCoeptis Therapeutics Holdings Inc
CEOMehalick (David)
Websitehttps://coeptistx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Coeptis Therapeutics Holdings Inc (COEP)?
The current price of Coeptis Therapeutics Holdings Inc (COEP) is 16.40.
What is the symbol of Coeptis Therapeutics Holdings Inc?
The ticker symbol of Coeptis Therapeutics Holdings Inc is COEP.
What is the 52-week high of Coeptis Therapeutics Holdings Inc?
The 52-week high of Coeptis Therapeutics Holdings Inc is 21.41.
What is the 52-week low of Coeptis Therapeutics Holdings Inc?
The 52-week low of Coeptis Therapeutics Holdings Inc is 6.26.
What is the market capitalization of Coeptis Therapeutics Holdings Inc?
The market capitalization of Coeptis Therapeutics Holdings Inc is 579.55M.
What is the Earnings Per Share (EPS TTM) of Coeptis Therapeutics Holdings Inc (COEP)?
The Earnings Per Share (EPS TTM) of Coeptis Therapeutics Holdings Inc (COEP) is -2.81.